The same set of clinical data on Cabometyx and Tecentriq in prostate cancer has led to two distinct regulatory plans between ...

Sandoz and United Therapeutics’ years-long dispute over a generic to pulmonary arterial hypertension med treprostinil has ...

Following a meeting with the FDA’s Gastrointestinal Drug Advisory Committee Friday, the future of Intercept’s rare liver ...

Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U ...

Almirall has rolled out a new campaign for World Atopic Eczema Day, kicking off its “The T | Almirall has rolled out a new ...

PhRMA is pushing the FDA to expand drug manufacturers’ powers to correct misinformation about their products, i | PhRMA is ...

Palisade Bio is fortifying its brand image. The California-based biotech on Monday unveiled a new logo and website design, ...

Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate (mHSPC) cancer with a combination free of ...

Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out ...

We’re finally moving towards a causality-based nosology for psychiatry: specific symptoms with defined biological ...

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...